microarray-based 495-gene-expression classifier cupprint (Agendia BV)
90
Structured Review
Agendia BV
microarray-based 495-gene-expression classifier cupprint
Microarray Based 495 Gene Expression Classifier Cupprint, supplied by Agendia BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray-based+495-gene-expression+classifier/18+gene+coloprint+gene+expression+profile/pmc02823680-169-6-10
Average 90 stars, based on 1 article reviews
Microarray Based 495 Gene Expression Classifier Cupprint, supplied by Agendia BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray-based+495-gene-expression+classifier/18+gene+coloprint+gene+expression+profile/pmc02823680-169-6-10
Average 90 stars, based on 1 article reviews
microarray-based 495-gene-expression classifier cupprint - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: Colorectal cancer concurrent gene signature based on coherent patterns between genomic and transcriptional alterations Article Snippet: Other signatures included the Article Title: Prognostic Value of IGF2 mRNA-Binding Protein 3 (IGF2BP3) Intratumoral Expression in Melanoma Patients at the Time of Diagnosis: Comparative Analysis of RT-qPCR Versus Immunohistochemistry. Article Snippet: Examples of these are the microarray-based clinical tests, such as Article Title: Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma Article Snippet: Additionally, an Article Title: From tumour heterogeneity to advances in precision treatment of colorectal cancer. Article Snippet: | In recent years, the high heterogeneity of colorectal cancer (CRC) has become evident.. Hence, biomarkers need to be developed that enable the stratification of patients with CRC into different prognostic subgroups and in relation to response to therapies, according to the distinctive tumour biology.. Currently, only RAS-mutation status is used routinely as a negative predictive marker to avoid treatment with anti-EGFR agents in patients with metastatic CRC, and mismatch-repair status can guide the use of adjuvant chemotherapy in patients with early stage colon cancer. Microarray:Article Title: Cancer of Unknown Primary origin in the genomic era: Elucidating the dark box of cancer. Article Snippet: Cancer of Unknown Primary (CUP) comprises a heterogeneous disease group with diagnosis of metastatic malignancy in the absence of an identifiable primary site after diagnostic work up.. CUP may either resemble a specific primary tumor site sharing common clinicopathological characteristics and prognosis, or present as a distinct disease entity with undifferentiated pathological features, usually bearing dismal prognosis.. Diagnosis and management have traditionally been based on clinicopathological characteristics and therapeutic strategies have been mainly empirical. Expressing:Article Title: Cancer of Unknown Primary origin in the genomic era: Elucidating the dark box of cancer. Article Snippet: Cancer of Unknown Primary (CUP) comprises a heterogeneous disease group with diagnosis of metastatic malignancy in the absence of an identifiable primary site after diagnostic work up.. CUP may either resemble a specific primary tumor site sharing common clinicopathological characteristics and prognosis, or present as a distinct disease entity with undifferentiated pathological features, usually bearing dismal prognosis.. Diagnosis and management have traditionally been based on clinicopathological characteristics and therapeutic strategies have been mainly empirical. Gene Expression:Article Title: Genomic Classifier ColoPrint Predicts Recurrence in Stage II Colorectal Cancer Patients More Accurately Than Clinical Factors Article Snippet: .. Gene Expression Analysis The Article Title: Genomic Classifier ColoPrint Predicts Recurrence in Stage II Colorectal Cancer Patients More Accurately Than Clinical Factors Article Snippet: .. The Diagnostic Assay:Article Title: Transcriptomics in cancer diagnostics: developments in technology, clinical research and commercialization. Article Snippet: Transcriptomics in cancer diagnostics: developments in technology, clinical research and commercialization Monica Sager, Nai Chien Yeat, Stefan Pajaro-Van der Stadt, Charlotte Lin, Qiuyin Ren & Jimmy Lin To cite this article: Monica Sager, Nai Chien Yeat, Stefan Pajaro-Van der Stadt, Charlotte Lin, Qiuyin Ren & Jimmy Lin (2015): Transcriptomics in cancer diagnostics: developments in technology, clinical research and commercialization, Expert Review of Molecular Diagnostics, DOI: 10.1586/14737159.2015.1105133 To link to this article: http://dx.doi.org/10.1586/14737159.2015.1105133 |